Editas Medicine, Inc. (NASDAQ:EDIT) traded at $28.42 at last check on Friday, Nov 20, making an upward move of 1.39% on its previous day’s price.
Looking at the stock we see that its previous close was $28.03 and the beta (5Y monthly) reads 1.84 with the day’s price range being $27.33 – 28.61. The company has a 12-month trailing PE ratio of 0. In terms of its 52-week price range, EDIT has a high of $39.96 and a low of $14.01. The company’s stock has gained about -11.89% over that past 30 days.
Editas has a market cap of $1.68 Billion and is expected to release its quarterly earnings report on November 05, 2020. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the EDIT stock to lose ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of -$0.75, with the EPS growth for the year raised at -$1.71 for 2020 and -$3.32 for next year. These figures represent -0.36% and at 0.94% growth in EPS for the two years respectively.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $6.27 Million, with a low of $2Million and a high of $10.7 Million. The median projection represents growth adding up to -49% compared to sales earnings for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecasts for 2020 are expected to hit $85.02 Million, or +314.1% up from figures reported last year.
On the other hand, looking at the outlook for the EDIT stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of Hold. Long term indicators on average place the stock in the category of Hold.
Let’s briefly compare Editas (EDIT) stock to its peers. We find that today’s price change of +1.39% and +16.43% over the past 12 months for EDIT betters that of Bristol-Myers Squibb Company (BMY), which has seen its stock price fall -0.77% in the latest trading session and is +8.37% over the last one year. Another of its peers Amgen Inc (AMGN) has dropped -0.67% today, but is -2.04% down over the past year, while Gilead Sciences Inc (GILD) is also up 1.39% yet its price remains in the green at 16.43% over the same period. Bristol-Myers has a P/E ratio of 0 compared to Editas 0 and Amgen’s 17.99. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at -0.68% and -0.75%, respectively, in early deals.
Coming back to Editas Medicine, Inc. (NASDAQ:EDIT), we note that the average 3-month trading volume was 867.57 Million, while that of the preceding 10-day period stands at 842.89 Million. Current shares outstanding are 62.33 Million.
According to data from Thomson Reuters, insiders hold 1.37% of the company’s shares while institutions hold 85.72%. The data shows that short shares as of October 29, 2020, stood at 11.29 Million at a short ratio of 12.8. This represents a 18.12% Short interest in Shares outstanding on October 29, 2020. Shares short rose in October from the previous month at 10.47 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock -4.02% down in year-to-date price movement.